{"url_path":"/sec/avns/8-k/2026-07-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1606498/0001606498-26-000085-index.html","accession_number":"0001606498-26-000085","cik":"0001606498","ticker":"AVNS","issuer_name":"AVANOS MEDICAL, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1606498/0001606498-26-000085-index.html","primary_entity_key":"0001606498","primary_entity_name":"AVANOS MEDICAL, INC."},"word_count":156,"has_tables":true,"body_markdown":"Item 7.01    Regulation FD Disclosure\n\nOn July 2, 2026, Avanos Medical, Inc., a Delaware corporation (the “Company”), issued a press release announcing the receipt of all required regulatory approvals to complete the pending acquisition of the Company by affiliates of investment funds advised by American Industrial Partners. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\nThe information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing."}